- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01438593
Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke
July 31, 2012 updated by: Shinn-Zong Lin, China Medical University Hospital
An Exploratory Clinical Trial to Assess Treatment of Chronic Ischemic Stroke With Brain Transplants of Purified CD34+ Umbilical Cord Blood Stem Cells
The purpose of the study is to determine the safety and possible effectiveness of brain transplants of CD34+ stem cells obtained from umbilical cord blood (UCB) to treat stroke.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will use CD34+ cells (a special kind of cell that is believed to be a stem cell) isolated from UCB (blood obtained at birth from the umbilical cord blood of babies).
StemCyte, a leading accredited UCB banking company with branches in the United States and Taiwan, will provide the units of UCB that match at least 5 out of 6 HLA (human leukocyte antigens) for transplantation.
The HLA-matching is the same as that used to match cells and organs for transplantation so that the body does not reject the cells.
We will isolate CD34 cells from these units, purified them, suspend the cells in solution (1 ml containing 2-8 million cells), and inject the cells into brain around the site damaged by the stroke
Study Type
Interventional
Enrollment (Anticipated)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Woei-Cherng Shyu, M.D.;PhD.
- Phone Number: 7813 886-4-22052121
- Email: shyu9423@gmail.com
Study Locations
-
-
-
Taichung, Taiwan, 244
- China Medical University Hospital
-
Contact:
- Woei-Cherng Shyu, M.D.;PhD.
- Phone Number: 7813 886-4-22052121
- Email: shyu9423@gmail.com
-
Principal Investigator:
- Shinn-Zong Lin, M.D.;PhD.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects can be of either gender and must be between 35 through 75 years of age.
- Subjects must have had ischemic stroke more than 6 and less than 60 months ago.
- Subjects must have stable hemiplegia or hemiparesis condition at least for 3 months.
- Subjects must have stroke-induced clinical deficits affecting motor, perceptual, or language functions, with a National Institutes of Health Stroke Scale (NIHSS) of 5-15.
- Subjects must have stroke in the middle cerebral artery territory.
- Subjects must have an available umbilical cord blood unit that has an HLA-match of at least 5:6 (HLA-A, -B, and -DR).
- Subjects must be able to read and understand the informed consent form that has been approved by the appropriate Institutional Review Board (IRB). The subject must sign and date the informed consent form before any study-specific procedures. (Note: If a subject consents to participation but is not in a position to sign and date the informed consent form personally because of his or her physical conditions, the consent form must be confirmed orally at the time of consent, marked or finger printed by the subject voluntarily). The informed consent procedure must be observed by an independent witness who is present throughout the whole informed consent process and sign the consent form.
Exclusion Criteria:
- Subject has evidence of a non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or intraventricular hemorrhage or MRI has shown that the occlusion is not in the middle cerebral artery territory.
- Pregnant or lactating women.
- History of alcohol or drug abuse in the previous 3 months.
Subjects must not have the following conditions in documents:
- significant renal, cardiovascular, hepatic, or psychiatric disease
- abnormal blood coagulation parameters,
- immunodeficiency (e.g. AIDS)
- tumors, leukemia, and other cancer that may interfere with the clinical trial protocol
- infectious diseases, including hepatitis, or other conditions that may be a contraindication to the planned therapies and evaluation.
- Subject must not be currently participating in another investigational study or taking any investigational drug within the last four weeks before the screening of this study.
- Any other condition that, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol and would not be suitable to perform a surgery or to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HUCB, Medicine, Rehabilitation
Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
|
Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in NIH Stroke Scale (NIHSS)
Time Frame: Change from baseline in NIHSS at 1 weeks
|
Evaluate change from Baseline in NIHSS at 1 week
|
Change from baseline in NIHSS at 1 weeks
|
Change from Baseline in NIH Stroke Scale(NIHSS)
Time Frame: Change from Baseline in NIHSS at 2 weeks
|
Evaluate change from Baseline in NIHSS at 2 weeks
|
Change from Baseline in NIHSS at 2 weeks
|
Change from baseline in NIH Stroke Scale
Time Frame: Change from baseline in NIHSS at 4 weeks
|
Evaluate change from baseline in NIHSS at 4 weeks
|
Change from baseline in NIHSS at 4 weeks
|
Change from baseline in NIH Stroke Scale ( NIHSS)
Time Frame: Change from baseline in NIHSS at 12 weeks
|
Evaluate change from baseline in NIHSS at 12 weeks
|
Change from baseline in NIHSS at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Brain Image
Time Frame: Change from baseline in Brain Image at 1 week
|
Brain Image will be performed by MRI.
The MRI evaluation includes DEI, T1W, T2W, MRS, and DTI, and change from baseline will be evaluated at 1 week
|
Change from baseline in Brain Image at 1 week
|
Change from baseline in Brain Image
Time Frame: Change from baseline in Brain Image at 4 weeks
|
Brain Image will be performed by MRI.
The MRI evaluation includes DEI,T1W,T2W,MRS and DTI , and evaluate the change from baseline at 4 weeks
|
Change from baseline in Brain Image at 4 weeks
|
Change from baseline in Brain Image
Time Frame: Change from baseline in Brain Image at 6 months
|
Brain Image will be performed by MRI.MRI image includes DEI,T1W, T2W, and DTI, and change from baseline will be evaluated at 6 months.
|
Change from baseline in Brain Image at 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shinn-Zong Lin, M.D.;PhD., China Medical University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
September 7, 2011
First Submitted That Met QC Criteria
September 21, 2011
First Posted (Estimate)
September 22, 2011
Study Record Updates
Last Update Posted (Estimate)
August 2, 2012
Last Update Submitted That Met QC Criteria
July 31, 2012
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Infarction
- Cerebral Arterial Diseases
- Intracranial Arterial Diseases
- Infarction
- Stroke
- Ischemic Stroke
- Brain Ischemia
- Ischemia
- Cerebral Infarction
- Infarction, Middle Cerebral Artery
Other Study ID Numbers
- DMR97-IRB-178-4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemia
-
University Hospital, Strasbourg, FranceTerminatedVascular Surgery | Ischemia-reperfusion | Ischemia PreconditioningFrance
-
Beytepe Murat Erdi Eker State HospitalCompletedAnterior Segment Ischemia (Diagnosis)
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
The First Affiliated Hospital with Nanjing Medical...RecruitingHepatic IschemiaChina
-
Maastricht University Medical CenterUnknownIschemia-ReperfusionNetherlands
-
Egyptian Cerebro-Cardio-Vascular AssociationUnknownRisk Factor, Cardiovascular | Ischemia, Myocardial | Ischemia, Cerebral
-
Technische Universität DresdenRecruitingRetinal IschemiaGermany
-
Centre Hospitalier Universitaire de NiceCompleted
-
Attikon HospitalUniversity Hospital of PatrasCompleted
-
Beth Israel Deaconess Medical CenterWithdrawn
Clinical Trials on Intercerebral implantation of allogenic CD34+ stem cell
-
China Medical University HospitalCompletedStroke | Middle Cerebral Artery InfarctionTaiwan
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedChronic Graft-Versus-Host DiseaseSpain
-
University Medical Centre LjubljanaRecruitingHeart Failure | Mechanical Circulatory SupportSlovenia
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
Shenzhen Second People's HospitalGuangzhou Women and Children's Medical Center; Shenzhen UniversityRecruitingAdrenoleukodystrophy | Metachromatic LeukodystrophyChina
-
Hospital Universitario Dr. Jose E. GonzalezSuspendedCardiomyopathy, DilatedMexico
-
Odense University HospitalUnknown
-
Hanyang University Seoul HospitalMinistry of Health & Welfare, Korea; Corestem, Inc.RecruitingSystemic Lupus ErythematosusKorea, Republic of
-
Acibadem UniversityCompletedRetinitis Pigmentosa | Stem Cell TransplantTurkey
-
Anterogen Co., Ltd.CompletedDiabetic Foot UlcerKorea, Republic of